Cibus, Inc. Stock Nasdaq

Equities

CLXT

US17166A1016

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-06-28 pm EDT 5-day change 1st Jan Change
9.85 USD +3.79% Intraday chart for Cibus, Inc. -1.50% -49.85%
Sales 2024 * 2.17M Sales 2025 * 8.69M Capitalization 226M
Net income 2024 * -82M Net income 2025 * -88M EV / Sales 2024 * 104 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 26 x
P/E ratio 2024 *
-3.23 x
P/E ratio 2025 *
-4.19 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.74%
More Fundamentals * Assessed data
Dynamic Chart
1 week-1.50%
Current month-31.88%
1 month-34.07%
3 months-56.14%
6 months-51.04%
Current year-49.85%
More quotes
1 week
8.31
Extreme 8.31
10.38
1 month
8.31
Extreme 8.31
15.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 -
Director of Finance/CFO 67 -
President 61 -
Members of the board TitleAgeSince
Chief Executive Officer 71 -
Director/Board Member 81 -
Director/Board Member 76 -
More insiders
Date Price Change
24-06-28 9.85 +3.79%
24-06-27 9.49 +4.75%
24-06-26 9.06 +0.67%
24-06-25 9 -5.86%
24-06-24 9.56 -4.40%

Delayed Quote Nasdaq, June 28, 2024 at 04:00 pm EDT

More quotes
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
9.85 USD
Average target price
23 USD
Spread / Average Target
+133.50%
Consensus